Phospho-CASR (Thr888) Antibody

Shipped with Ice Packs
In Stock

Description

Calcium-Dependent Phosphorylation Dynamics

Experimental data demonstrate a biphasic relationship between extracellular calcium (Ca²⁺ₒ) concentrations and Thr888 phosphorylation:

Ca²⁺ₒ (mM)Phosphorylation Level (160 kDa form)Significance
0.5BaselineControl condition
2.55× increasePeak response
5.0Return to baselineReceptor feedback

Phorbol ester (PMA) treatment induces rapid phosphorylation:

  • 2 min: Significant increase (p<0.05)

  • 10 min: Maximum phosphorylation (p<0.001)

  • 15-20 min: Gradual decline

Functional Implications

  1. Receptor Regulation: High Ca²⁺ₒ (5 mM) enhances PP2A-mediated dephosphorylation by 35% within 30 seconds (p<0.05)

  2. Signaling Crosstalk: PKC inhibition (GF109203X) blocks phosphorylation, confirming kinase dependency

  3. Maturation State: Differentiated response between:

    • 140 kDa core-glycosylated CaSR (sustained phosphorylation)

    • 160 kDa mature membrane-bound form (transient response)

Technical Validation

Specificity Controls:

  • No cross-reactivity with non-phosphorylated CaSR

  • Recognizes both human and rodent orthologs

  • Distinct bands at 140/160 kDa confirm proper glycosylation status

Experimental Optimization:

  • Recommended blocking buffer: 5% BSA in TBST

  • Antigen retrieval required for formalin-fixed samples

  • Compatible with reducing and non-reducing conditions

Regulatory Status

  • RUO Classification: Strictly for research purposes

  • Validation Level:

    • Epitope-specific affinity purification

    • Batch-to-batch consistency testing

    • Negative controls in ≥3 cell models

Product Specs

Form
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship your orders within 1-3 business days of receipt. Delivery times may vary depending on the method of purchase and your location. Please contact your local distributor for specific delivery details.
Synonyms
Ca sensing receptor antibody; Ca2+ sensing receptor 1 antibody; Ca2+ sensing receptor antibody; Calcium sensing receptor antibody; CAR antibody; CaSR antibody; CASR_HUMAN antibody; EIG8 antibody; Extracellular calcium sensing receptor antibody; Extracellular calcium sensing receptor [Precursor] antibody; Extracellular calcium-sensing receptor antibody; FHH antibody; FIH antibody; GPRC2A antibody; HHC antibody; HHC1 antibody; Hypocalciuric hypercalcemia 1 antibody; Hypocalciuric hypercalcemia 1 severe neonatal hyperparathyroidism antibody; MGC138441 antibody; NSHPT antibody; Parathyroid Ca(2+) sensing receptor 1 antibody; Parathyroid Cell calcium sensing receptor antibody; Parathyroid Cell calcium-sensing receptor antibody; PCAR 1 antibody; PCaR1 antibody
Target Names
Uniprot No.

Target Background

Function
The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that detects changes in extracellular calcium ion concentrations. It plays a crucial role in maintaining calcium homeostasis. CaSR senses fluctuations in circulating calcium levels and regulates the production of parathyroid hormone (PTH) in parathyroid glands. The receptor's activity is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. Activation of this G-protein-coupled receptor requires a co-agonist mechanism: aromatic amino acids, such as tryptophan (Trp) or phenylalanine (Phe), act in conjunction with divalent cations, such as calcium or magnesium, to achieve full receptor activation.
Gene References Into Functions
  1. Cytogenetic analysis was conducted on 23 patients with Sagliker syndrome. The study identified base alterations and deletions in exons 2 and 3 of the CaSR gene. PMID: 28263480
  2. This study suggests that ischemia/reperfusion-induced MCPIP1 expression regulates the migration and apoptosis of human vascular endothelial cells. This occurs through the modulation of high mobility group box 1 (HMGB1) and CaSR, respectively. PMID: 29379093
  3. Expressions of p27(Kip1) and CaSR were found to be decreased in patients with primary hyperparathyroidism. PMID: 29589297
  4. This research presents a novel concept: CaSR activation stimulates autophagy in preadipocytes, which subsequently mediates the elevation of tumor necrosis factor alpha (TNFalpha) production. PMID: 30251678
  5. The findings of this study highlight a potential cellular protective mechanism against cadmium (Cd)-induced kidney injury, involving the activation of a CaSR-mediated protective pathway in renal cells. PMID: 29348484
  6. These findings suggest an inhibitory role for CaSR in endometrial cancer. Therefore, reduced CaSR expression may be a valuable predictor for endometrial cancer progression. PMID: 29348629
  7. This study found that subjects carrying the G allele of rs6776158 (AG and GG) had a significantly higher risk of nephrolithiasis compared to the AA genotype. The results suggest that rs6776158 polymorphism may increase the risk of nephrolithiasis in the Chinese population. PMID: 30407299
  8. The variant allele of CASR rs1801725, both alone and in combination with the variant allele of rs7652589, increases the risk of more advanced secondary hyperparathyroidism. PMID: 29763933
  9. This study confirms the expression of CaSR in human bone marrow-derived mesenchymal stem cells (BM-MSCs). It also reveals a significant role for the interaction between CaSR and PTH1R in regulating MSC fate and the selection of pathways for bone formation. PMID: 29915064
  10. Genetic polymorphism of the calcium-sensing receptor is associated with breast cancer risk. PMID: 29387985
  11. The low prevalence of CaSR autoantibodies suggests a very low level of subclinical parathyroid autoimmunity in autoimmune polyendocrine syndromes (APS) types 2, 3, and 4. PMID: 28941288
  12. CaSR Arg990Gly polymorphism is associated with the risk of nephrolithiasis development in a Chinese population. PMID: 28609763
  13. TRPC1 is a primary candidate in forming the store-operated calcium entry (SOCE) channel that stimulates CaSR-induced SOCE and nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). PMID: 28791397
  14. The c.2195A>G, p.(Asn732Ser) mutation in exon 7 of the CaSR gene leads to hypocalcemia. This mutation has not been previously reported in the medical literature. Additionally, this mutation may be linked to premature baldness. PMID: 28741586
  15. CASR SNPs may partially explain differences in the clinical manifestations of chronic kidney disease-mineral and bone disorder (CKD-MBD) between European and African ancestry populations. They may also influence the biochemical response to cinacalcet in many patients. PMID: 28630081
  16. Decreased sensitivity of the CaSR to calcium due to inactivating polymorphisms at rs1801725, may predispose up to 20% of breast cancer cases to high circulating calcium-associated larger and/or aggressive breast tumors. PMID: 28764683
  17. This study demonstrates that the A allele of rs7652589 is a risk allele for nephrolithiasis-related end-stage renal disease. The AA genotype is associated with more severe secondary hyperparathyroidism (higher calcium and parathormone concentrations). PMID: 27739473
  18. Polymorphism of the Calcium-Sensing Receptor Gene is associated with Breast Cancer Risk. [review] PMID: 29504802
  19. Data indicate that calcium ions (Ca2+), through CaR-mediated signaling, induce filamin A cleavage and promote migration in androgen receptor (AR)-deficient and highly metastatic prostate cancer cells. PMID: 27206800
  20. GPR64 is expressed on the cell surface of parathyroid cells, is overexpressed in parathyroid tumors, and physically interacts with the CaSR. PMID: 27760455
  21. This study demonstrates for the first time that calcium exerts an oncogenic action in the stomach through activation of CaSR and transient receptor potential vanilloid 4 (TRPV4) channels. Both CaSR and TRPV4 are involved in Ca2+-induced proliferation, migration, and invasion of gastric cancer cells through a Ca2+/AKT/beta-catenin relay. This occurs only in gastric cancer cells or normal cells overexpressing CaSR. PMID: 28951460
  22. This study reports the use of mutagenesis with a novel analytical approach and molecular modeling to develop an "enriched" picture of structure-function requirements for interaction between extracellular calcium (Ca(2+)o) and allosteric modulators within the CaSR's 7 transmembrane (7TM) domain. PMID: 27002221
  23. Filamin A (FLNA) is downregulated in parathyroid tumors and parallels the CASR expression levels. Loss of FLNA reduces CASR mRNA and protein expression levels and the CASR-induced extracellular signal-regulated kinase (ERK) phosphorylation. FLNA is involved in receptor expression, membrane localization, and ERK signaling activation of both 990R and 990G CASR variants. PMID: 27872158
  24. A father and daughter with asymptomatic chronic hypocalcemia with low parathyroid hormone and inappropriate urinary calcium excretion had a missense mutation in exon 7: c.2621G>T (p.Cys874Phe). PMID: 27663953
  25. These results support the emerging potential of CaSR as a therapeutic target in metastatic breast cancer. Pharmacological modulation of CaSR could reduce interleukin-6 (IL-6). PMID: 27477783
  26. These structures reveal multiple binding sites for Ca(2+) and PO4(3-) ions. Both ions are crucial for the structural integrity of the receptor. While Ca(2+) ions stabilize the active state, PO4(3-) ions reinforce the inactive conformation. PMID: 27434672
  27. The endoplasmic reticulum-associated protein, OS-9, acts as a lectin in targeting the immature calcium-sensing receptor. PMID: 28419469
  28. Glucose acts as a positive allosteric modulator of CaSR. PMID: 27613866
  29. These studies indicate that CaSR activation impairs glucose tolerance through a combination of alpha- and beta-cell defects, and also influences pancreatic islet mass. PMID: 28575322
  30. Minor alleles rs7652589 and rs1501899 are associated with reduced CaSR expression in neuroblastic tumors and neuroblastoma cell lines in which the CASR gene promoter P2 is not hypermethylated. PMID: 27862333
  31. Calcium exerts its effects on cartilaginous endplates matrix protein synthesis through activation of the extracellular calcium-sensing receptor. PMID: 27452962
  32. Polymorphic variations in vitamin D receptor (VDR) and CASR may be associated with survival after a diagnosis of colorectal neoplasms. PMID: 28765616
  33. CaSR and adaptor protein 2 sigma 1 (AP2S1) sequencing is worthwhile in patients with familial hyperparathyroidism and a phenotype suggesting familial hypocalciuric hypercalcemia, as it can diagnose up to 50% of cases. PMID: 28176280
  34. Reduced expression of the CaSR is correlated with activation of the renin-angiotensin system. This induces increased vascular remodeling and vascular smooth muscle cell proliferation, and is associated with essential hypertension in the spontaneously hypertensive rat (SHR) model and in the Han Chinese population. PMID: 27391973
  35. CaSR exerts a suppressive function in pancreatic tumorigenesis through a novel sodium-calcium exchanger 1 (NCX1)/Ca(2+)/beta-catenin signaling pathway. PMID: 27108064
  36. In white individuals, CaSR gene SNP rs1801725 was associated with serum calcium but not with the risk of diabetes. PMID: 27510541
  37. Tumor CaSR expression is associated with an increased risk of lethal prostate cancer, particularly in tumors with low VDR expression. PMID: 27115058
  38. Functional interaction of upregulated CaSR and upregulated transient receptor potential canonical 6 (TRPC6) in pulmonary artery smooth muscle cells from idiopathic pulmonary arterial hypertension patients may play a significant role in the development and progression of sustained pulmonary vasoconstriction and pulmonary vascular remodeling. PMID: 26968768
  39. This is a prospective observational study that measures the expression of vitamin D (VD) metabolizing and signaling molecules and Ca(2+) sensing receptor (CaSR) in human Fallopian tube (FT) during the menstrual cycle and ectopic pregnancy (EP). PMID: 27770255
  40. CaSR expression was demonstrated in HepG2 cells and human liver samples. CaSR may contribute to obesity-associated hepatic metabolic consequences. PMID: 27565442
  41. Polymorphisms of the CASR gene increase the risk of primary hyperparathyroidism. PMID: 26710757
  42. Calcium oxalate-induced renal injury is related to CaSR-mediated oxidative stress and increased mitogen-activated protein kinase signaling, which subsequently leads to CaOx crystal adhesion. PMID: 27965733
  43. The detection of CaSR gene mutations is suitable to differentiate states of hypercalcemia and may help to avoid invasive procedures such as parathyroidectomies. PMID: 27926951
  44. This study identifies a novel loss-of-function mutation, G571W, in the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia. PMID: 26386835
  45. There is a significant correlation between in vitro functional impairment of the CaSR at physiologic calcium concentrations and the severity of alterations in calcium homeostasis in patients. PMID: 27666534
  46. Calcium-sensing receptor gene rs1801725 variants are not associated with susceptibility to colorectal cancer. PMID: 25124570
  47. Physiological fetal hypercalcemia, acting on the CaSR, promotes human fetal lung development via cyclic adenosine monophosphate (cAMP)-dependent opening of cystic fibrosis transmembrane conductance regulator (CFTR). PMID: 26911344
  48. CaSR and PTH1R signaling responses in cartilage and bone. [review] PMID: 26688334
  49. The calcium-sensing receptor may be involved in the modulation of inflammatory processes. [review] PMID: 26303192
  50. A986S polymorphism of CaSR is an independent predictor of PTH level in normocalcemic hyperparathyroidism patients, but not in asymptomatic hyperparathyroidism. PMID: 26332755

Show More

Hide All

Database Links

HGNC: 1514

OMIM: 145980

KEGG: hsa:846

STRING: 9606.ENSP00000420194

UniGene: Hs.435615

Involvement In Disease
Hypocalciuric hypercalcemia, familial 1 (HHC1); Hyperparathyroidism, neonatal severe (NSHPT); Hypocalcemia, autosomal dominant 1 (HYPOC1); Epilepsy, idiopathic generalized 8 (EIG8)
Protein Families
G-protein coupled receptor 3 family
Subcellular Location
Cell membrane; Multi-pass membrane protein.
Tissue Specificity
Expressed in the temporal lobe, frontal lobe, parietal lobe, hippocampus, and cerebellum. Also found in kidney, lung, liver, heart, skeletal muscle, placenta.

Q&A

What is the Phospho-CASR (Thr888) Antibody and what does it specifically detect?

The Phospho-CASR (Thr888) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of Calcium Sensing Receptor (CASR) only when phosphorylated at threonine 888. This antibody does not recognize non-phosphorylated CASR or other phosphorylation sites, making it valuable for studying specific CASR phosphorylation events . The specificity is achieved through careful purification processes where non-phospho specific antibodies are removed through chromatography using non-phosphopeptides .

What are the standard applications for Phospho-CASR (Thr888) Antibody in research?

The Phospho-CASR (Thr888) Antibody is validated for several research applications:

ApplicationTypical Dilution RangeNotes
Western Blot (WB)1:500-1:2000Most commonly used for quantification
Immunofluorescence (IF)1:200-1:1000Useful for cellular localization studies
ELISA1:10000-1:40000High sensitivity for quantitative analysis

The antibody is particularly useful for monitoring CASR phosphorylation status in response to various treatments or conditions, especially those affecting PKC activity or calcium signaling pathways .

What is the molecular and functional significance of CASR Thr888 phosphorylation?

CASR Thr888 is a substrate for receptor-induced, PKC-mediated feedback phosphorylation and plays a crucial role in receptor regulation. Functionally, Thr888 phosphorylation modulates CASR sensitivity to agonists and influences calcium-induced intracellular signaling patterns .

How should I optimize Western blot protocols for Phospho-CASR (Thr888) Antibody?

For optimal Western blot results with Phospho-CASR (Thr888) Antibody:

  • Sample preparation:

    • Use freshly prepared lysates whenever possible

    • Include phosphatase inhibitors (e.g., calyculin) in your lysis buffer to prevent dephosphorylation

    • Maintain samples at 4°C during processing

  • Protocol optimization:

    • Start with a 1:1000 dilution for initial testing

    • Use 5% BSA (not milk) for blocking and antibody dilution to reduce background

    • Include a positive control (e.g., lysates from cells treated with PKC activators like PMA)

    • Consider using PVDF membranes which may provide better signal for phospho-specific antibodies

  • Detection:

    • Expected molecular weight is approximately 120-140 kDa

    • Validate specificity using phosphopeptide competition assays

What controls are essential when using Phospho-CASR (Thr888) Antibody?

To ensure valid and interpretable results with Phospho-CASR (Thr888) Antibody, include the following controls:

  • Positive controls:

    • Lysates from cells treated with phorbol ester (PMA), which activates PKC and increases Thr888 phosphorylation

    • Samples with elevated extracellular calcium (2.5-5 mM) which has been shown to increase CASR(T888) phosphorylation

  • Negative controls:

    • Samples treated with PKC inhibitors

    • Lysates from cells expressing CASR(T888A) mutant

    • Samples pre-treated with calyculin (a protein phosphatase inhibitor) combined with PMA

  • Specificity controls:

    • Antigen competition assay using the phosphopeptide immunogen

    • Non-phosphorylated peptide controls to confirm phospho-specificity

How can I use Phospho-CASR (Thr888) Antibody to study the relationship between calcium sensing and PKC signaling pathways?

To investigate the complex interplay between calcium sensing and PKC signaling:

  • Temporal analysis of phosphorylation:

    • Design time-course experiments using calcium ionophores or extracellular calcium elevation (0.5 mM to 2.5-5 mM)

    • Monitor Thr888 phosphorylation at various timepoints (0-60 minutes)

    • Correlate with downstream signaling events using other markers

  • Pharmacological manipulation:

    • Use calcimimetics (e.g., NPS R-467) to potentiate CASR activity

    • Apply calcilytics (e.g., NPS-89636) to inhibit receptor function

    • Combine with PKC activators/inhibitors to dissect pathway crosstalk

  • Functional correlation:

    • Pair phosphorylation measurements with calcium oscillation imaging

    • Correlate Thr888 phosphorylation status with intracellular calcium dynamics

    • Use the antibody in conjunction with electrophysiology to correlate phosphorylation with channel activity

What experimental approaches can resolve contradictory results when studying CASR phosphorylation in different cell types?

When facing contradictory results across different experimental systems:

  • Cell-type specific regulation analysis:

    • Examine baseline PKC isoform expression in your cell types of interest

    • Compare phosphatase activity profiles between systems

    • Measure total CASR expression and membrane localization

  • Advanced methodological approaches:

    • Use phosphoproteomics to identify all phosphorylation sites on CASR simultaneously

    • Apply FRET/BRET-based biosensors to monitor conformational changes in real time

    • Employ super-resolution microscopy to visualize phospho-CASR clustering

  • Physiological significance assessment:

    • Compare results between recombinant systems and native tissue

    • Correlate phosphorylation with established functional readouts (Ca²⁺ oscillations, ERK activation)

    • Utilize transgenic models with T888A mutations for in vivo validation

What are the most common causes of false negatives when using Phospho-CASR (Thr888) Antibody, and how can I address them?

Common causes of false negatives include:

  • Rapid dephosphorylation:

    • Include phosphatase inhibitors in all buffers (calyculin has been specifically shown to block Thr888 dephosphorylation)

    • Process samples rapidly and maintain at 4°C

    • Consider using phosphatase inhibitor cocktails with broad specificity

  • Insufficient PKC activation:

    • Verify your PKC stimulation protocol with established PKC substrate phosphorylation

    • Use multiple PKC activators (PMA, bryostatin, etc.)

    • Optimize stimulation time (peak phosphorylation may be transient)

  • Technical factors:

    • Ensure antibody is stored properly (-20°C, avoid freeze-thaw cycles)

    • Try longer incubation times and optimize antibody concentration

    • Consider signal amplification systems for low abundance proteins

How can I quantitatively assess CASR phosphorylation dynamics across different experimental conditions?

For rigorous quantitative analysis of CASR phosphorylation:

  • Normalization strategies:

    • Always normalize phospho-signal to total CASR expression (requires parallel blots or stripping/reprobing)

    • Include loading controls appropriate for your experimental system

    • Consider using recombinant phosphorylated standards for absolute quantification

  • Advanced quantification methods:

    • Use fluorescent secondary antibodies rather than chemiluminescence for broader linear range

    • Employ internal standard curves if comparing across multiple blots

    • Consider phospho-flow cytometry for single-cell analysis of phosphorylation states

  • Temporal and spatial resolution:

    • For subcellular localization, combine IF using phospho-CASR antibody with markers for different cellular compartments

    • Use live cell imaging with phospho-specific biosensors for real-time dynamics

    • Consider FLIM-FRET approaches to monitor conformational changes associated with phosphorylation

What are the optimal storage and handling conditions for Phospho-CASR (Thr888) Antibody to maintain its specificity and sensitivity?

For maximum antibody performance and longevity:

  • Storage recommendations:

    • Store at -20°C for long-term (up to one year)

    • For frequent use, aliquot and store at 4°C for up to one month

    • Avoid repeated freeze-thaw cycles which can degrade antibody quality

  • Working solution preparation:

    • Dilute only the amount needed for immediate use

    • Use fresh dilutions for each experiment

    • Prepare dilutions in recommended buffers (typically PBS with 0.5% BSA)

  • Quality control measures:

    • Periodically test antibody performance using positive controls

    • Monitor for changes in background or signal intensity over time

    • Consider including standard curves in long-term studies to track antibody performance

How can I use Phospho-CASR (Thr888) Antibody to investigate the co-agonist activation mechanism of CASR?

To explore the complex co-agonist mechanism where aromatic amino acids (Trp/Phe) act with divalent cations (Ca²⁺/Mg²⁺):

  • Experimental design strategies:

    • Set up factorial experiments varying both aromatic amino acids and calcium concentrations

    • Monitor Thr888 phosphorylation as a readout of receptor activation

    • Compare phosphorylation patterns induced by different co-agonist combinations

  • Structure-function analysis:

    • Use the antibody to assess how mutations in amino acid binding sites affect phosphorylation

    • Combine with conformation-specific antibodies to link phosphorylation with structural changes

    • Correlate phosphorylation status with binding affinities of different co-agonists

  • Signaling pathway discrimination:

    • Determine if Thr888 phosphorylation differs when activated by calcium alone versus co-agonist combinations

    • Investigate whether different co-agonists lead to distinct patterns of receptor phosphorylation

    • Map the temporal relationship between co-agonist binding and Thr888 phosphorylation

What methodological approaches can I use to study the relationship between CASR phosphorylation and calcium oscillations in primary cell cultures?

For investigating the mechanistic link between CASR phosphorylation and calcium oscillations:

  • Integrated imaging approaches:

    • Combine calcium imaging using ratiometric dyes (Fura-2) with post-fixation phospho-CASR immunostaining

    • Develop correlative live-cell and immunofluorescence protocols to link real-time calcium dynamics with phosphorylation status

    • Use microfluidic systems for precise temporal control of extracellular stimuli

  • Genetic manipulation strategies:

    • Express phosphomimetic (T888D) or phospho-null (T888A) CASR mutants in primary cells

    • Use inducible expression systems to control timing of mutant expression

    • Apply CRISPR-Cas9 gene editing to introduce mutations at endogenous loci

  • Pharmacological precision tools:

    • Use specific PKC isoform inhibitors to identify which isoforms mediate Thr888 phosphorylation

    • Apply temporal inhibition protocols to determine critical windows for phosphorylation

    • Combine with phosphatase inhibitors (calyculin) to manipulate phosphorylation/dephosphorylation cycles

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.